Screener
Recursion Pharmaceuticals, Inc. RXRX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | 56,936 | 70,230 |
| Unearned revenue | 27,586 | 37,605 |
| Operating lease liabilities | 13,249 | 12,663 |
| Notes payable and financing lease liabilities | 9,443 | 9,091 |
| Total current liabilities | 119,886 | 147,707 |
| Unearned revenue, non-current | 112,818 | 114,012 |
| Operating lease liabilities, non-current | 39,193 | 46,647 |
| Notes payable and financing lease liabilities, non-current | 4,753 | 9,564 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s current debt?
- Recursion Pharmaceuticals, Inc. (RXRX) reported current debt of $9.44M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s current debt changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s current debt increased by 7.9% year-over-year, from $8.75M to $9.44M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s current debt?
- Over 2 years (2023 to 2025), Recursion Pharmaceuticals, Inc.'s current debt has grown at a 1389.1% compound annual growth rate (CAGR), from $41K to $9.09M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Recursion Pharmaceuticals, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude